ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Promoting Autophagy Mitigates Stress-Induced Remodeling in Patient iPSC-CMs with the Phospholamban R9C Mutation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Promoting Autophagy Mitigates Stress-Induced Remodeling in Patient iPSC-CMs with the Phospholamban R9C Mutation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Phospholamban (PLN) is a key regulator of adrenergic signaling and calcium homeostasis in cardiomyocytes. The PLN R9C mutation causes early-onset dilated cardiomyopathy (DCM) and premature death, yet the mechanisms underlying its pathogenic remodeling remain unclear. In this study, patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) harboring the PLN R9C and their isogenic corrected controls are generated to investigate the molecular and functional consequences of the mutation. At baseline, PLN R9C iPSC-CMs exhibit near-normal calcium handling but blunt β-adrenergic signaling and slightly enhanced contractility. Under functional stress induced by a pro-maturation medium, mutant cells develop marked sarcomere disarray, impaired calcium handling, elevated diastolic calcium, and reduced contractile force, whereas corrected cells show adaptive improvement. Transcriptomic and biochemical analyses reveal activation of proteostasis pathways but accumulation of PLN pentamers and impaired autophagic flux, suggesting that autophagic overload contributes to functional remodeling. Treatment with the autophagy activator metformin mitigates sarcomere disorganization, restores calcium homeostasis, and improves contractility in patient-derived iPSC-CMs. These findings are further validated in wild-type and genome-engineered PLN R9C iPSC-CMs. Collectively, the study demonstrates that PLN R9C drives stress-induced pathological remodeling by disrupting proteostasis, and that enhancing autophagic flux offers a promising therapeutic strategy for DCM patients carrying PLN mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.